Takeda And HUTCHMED Announce Marketing Authorization Application Of Fruquintinib For Previously Treated Metastatic Colorectal Cancer Validated By The European Medicines Agency
Portfolio Pulse from Benzinga Newsdesk
Takeda (TAK) and HUTCHMED (HCM) announced that the European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib, a treatment for adult patients with previously treated metastatic colorectal cancer. The application includes data from Phase 3 FRESCO-2 and FRESCO clinical trials.
June 15, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HUTCHMED's partnership with Takeda on fruquintinib has resulted in the marketing authorization application being validated by the EMA, potentially expanding the treatment's reach to European patients.
The validation of the marketing authorization application for fruquintinib by the EMA is a positive development for HUTCHMED, as it demonstrates the success of their partnership with Takeda in developing and potentially commercializing this innovative therapy for patients with advanced disease. If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the EU for previously treated metastatic CRC. This could lead to increased revenues and a positive impact on HUTCHMED's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Takeda's fruquintinib marketing authorization application has been validated by the EMA, potentially offering a new treatment for metastatic colorectal cancer patients.
The validation of the marketing authorization application for fruquintinib by the EMA is a positive development for Takeda, as it brings the company one step closer to potentially offering this innovative therapy to patients with advanced disease. If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the EU for previously treated metastatic CRC. This could lead to increased revenues and a positive impact on Takeda's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100